2016

Go to main content

Remdesivir for treatment of COVID-19 to continue in Denmark and Europe until further notice

| 24 November 2020 |

Remdesivir for the treatment of hospitalised COVID-19 patients will continue in Denmark and the rest of Europe, awaiting the collection of further data that will provide conclusive evidence on the medicine’s efficacy and safety.
The Danish Medicines Agency can again receive electronic adverse reaction reports via E2B

| 23 November 2020 |

Please be informed that the gateway for SUSAR submission is now available again. If You after 48 hours have submissions that are pending acknowledgements, please contact the Danish Medicines Agency.
Fourth contract ensuring access to a potential COVID-19 vaccine

| 19 November 2020 |

Denmark has entered into a fourth contract with a vaccine manufacturer that will ensure the delivery of vaccines for COVID-19; the contract is signed by the European Commission on behalf of the EU member states. The contract means that about 2 million people can be vaccinated against coronavirus, provided the vaccine is approved by the authorities.
EMA starts rolling review of corona vaccine from Moderna

| 17 November 2020 |

The European Medicines Agency, EMA, has started a rolling review of data from the clinical trials of a potential COVID-19 vaccine from the manufacturer Moderna. The EMA has previously started the same process for other potential vaccines from AstraZeneca and BioNTech/Pfizer.
Opens today: New Data Analytics Center is to give people better and safer medicines and medical devices

| 16 November 2020 |

Today, the Danish Medicines Agency officially opens its new Data Analytics Center (DAC), a center that is to translate information and data about medicines and medical devices into knowledge that will benefit the general public. Objective: Better and safer medicines and medical devices.
The Danish Medicines Agency is replacing its register of medicines

| 13 November 2020 |

The Danish Medicines Agency´s current register of medicines – called KAT – is being replaced with a new and improved register. The new register is built on a Microsoft Dynamic CRM-platform and has been named “LEOPARD”, which is an abbreviation for “The Danish Medicines Agency´s Electronic Information- Packaging and Address-register for Denmark”. LEOPARD is scheduled to be implemented on November 23, 2020.
The Danish Medicines Agency cannot receive electronic adverse drug reactions via E2B in the period November 19th from 10:00 CET to November 24th

| 11 November 2020 |

Due to implementation of a new IT-system is it not possible for the Danish Medicines Agency to receive electronic adverse drug reactions (SUSARs) via E2B (DKMAEUDRA) in the period November 19th (10:00 CET) to November 24th 2020. Submissions to EVCTMPROD are not affected.
Opioid use in Denmark is decreasing

| 04 November 2020 |

Total sales of opioids have decreased by more than 20 per cent in the past four years, and there are now fewer Danes who use the most common type of opioid, tramadol. So reveals two new studies from the Danish Health Data Authority and the Danish Medicines Agency.

Share by mail

...

| 24 November 2020 |

| 23 November 2020 |

| 19 November 2020 |

| 17 November 2020 |

| 16 November 2020 |

| 13 November 2020 |

| 11 November 2020 |

| 04 November 2020 |

Time